Search Results for "Rituximab Patent"

12:02 EST 22nd December 2014 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Drug Delivery - news, views, blogs

Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  Drug delivery technologies are patent protected formulat...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

[News] Rituximab for low-grade follicular lymphoma?

Retreatment with rituximab on an as-needed basis provides comparable disease control with a lower total rituximab dose compared with maintenance rituximab for low grade follicular lymphoma, according ...

Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma

In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardle...

[Comment] Towards a chemotherapy-free approach in indolent lymphoma

With the introduction of rituximab 20 years ago, treatment of advanced stage indolent B-cell lymphoma has changed greatly since the first evidence that we can improve survival of patients with this in...

Patient access to rituximab in emerging markets

A Pfizer-sponsored study looking at access to the oncology treatment rituximab has revealed that use of this important drug would increase across all therapy types and markets if a biosimilar was avai...

Rituximab for ANCA-Associated Vasculitides

After cyclophosphamide induction, three patients (5%) experienced major relapse on rituximab vs 17 (29%) on azathioprine in an unblinded trial. Medscape Medical News

PatentStat.com to Rank Patent Attorneys and Patent Examiners

PatentStat.com is a new patent-related website that claims to use peer-reviewed patent valuation methodologies to rank patent attorneys and to profile patent examiners. PatentStat uses comprehensive ...

U.S. Food and Drug Administration lässt Zydelig (Idelalisib) von Gilead für Rezidive von chronischer lymphozytischer Leukämie, follikulärem Lymphom und kleinzelligem B-Zellen-Lymphom zu

-- 82-prozentige Senkung des Risikos eines Fortschreitens der Erkrankung und des Sterblichkeitsrisikos bei Kombination mit Rituximab im Vergleich mit Rituximab alleine bei Patienten mit Rezidiven ...

RheumShorts: MRI in RA, Fostamatinib, Statins and Rituximab (CME/CE)

(MedPage Today) -- Studies this week in Annals of the Rheumatic Diseases highlighted the potential role for MRI in predicting progression in early rheumatoid arthritis (RA), negative results with fost...

Matching PubMed Articles

Patent Highlights.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

First-to-invent versus first-to-file: impact of the AIA.

On March 16, 2013, the USPTO switched from a 'first-to-invent' to a 'first-to-file' patent system. Under the 2011 America Invents Act, patents will be awarded to the first inventor to file a patent ap...

Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.

Using rituximab, we have performed successful ABO-incompatible kidney transplantations in recipients without splenectomy as well as in those with high pretransplant anti-A/B antibody titers. A common ...

Scope of protection of a patent directed to prodrugs, metabolites and the like.

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement